Protein profiles distinguish stable and progressive chronic lymphocytic leukemia

• Published in: Leukemia & lymphoma Vol. 57; no. 5; pp. 1033 - 1043
• Main Authors: Huang, Pauline Y., Mactier, Swetlana, Armacki, Natalie, Giles Best, O., Belov, Larissa, Kaufman, Kimberley L., Pascovici, Dana, Mulligan, Stephen P., Christopherson, Richard I.
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 03.05.2016
• Subjects: Biomarkers, Tumor; Chromatography, Liquid; Chronic lymphocytic leukemia; Cluster Analysis; Disease Progression; Humans; Immunophenotyping; iTRAQ; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis; Leukemia, Lymphocytic, Chronic, B-Cell - metabolism; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; mass spectrometry; Neoplasm Staging; Phenotype; Prognosis; prognostic markers; Proteome; proteomics; Proteomics - methods; selected reaction monitoring; Tandem Mass Spectrometry; iTRAQ; mass spectrometry; Chronic lymphocytic leukemia; prognostic markers; proteomics; selected reaction monitoring

Patients with a stable chronic lymphocytic leukemia (CLL) double their blood lymphocyte count in >5 years, but may develop progressive disease with lymphocytes doubling in <12 months. To identify a protein signature for progressive CLL, whole cell extracts of peripheral blood mononuclear cells...